Lumasiran ALN-G01,95.37%
产品编号：Bellancom-132588| CAS NO：1834610-13-7
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，
Lumasiran ALN-G01
| 产品介绍 | Lumasiran (ALN-G01) 是一种 siRNA 化合物，通过靶向乙醇酸氧化酶 (glycolate oxidase) 减少肝脏草酸的产生。Lumasiran 通过沉默编码乙醇酸氧化酶的基因，消耗乙醇酸氧化酶，从而抑制草酸的合成，草酸是一种与原发性高草酸尿1型 (PH1) 表现直接相关的有毒代谢物。 |
|---|---|
| 生物活性 | Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1). |
| 体外研究 |
Lumasiran reduced urinary oxalate excretion, the cause of progressive kidney failure in PH1. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. |
| 体内研究 |
Lumasiran is a subcutaneously administered, liver-directed RNA interference (RNAi) therapeutic agent. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. |
| 体内研究 |
Lumasiran is a subcutaneously administered, liver-directed RNA interference (RNAi) therapeutic agent. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. |
| 性状 | Solid |
| 溶解性数据 |
In Vitro:
H2O : 100 mg/mL (Need ultrasonic) In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
*以上所有助溶剂都可在 西域 网站选购。
|
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 |
-20°C, stored under nitrogen, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture) |
| 参考文献 |
浙公网安备 33010802013016号